2. Immunology/Inflammation
  3. Fc Receptor (FcR) C-type Lectin-like Receptors (CTLRs)
  4. 23ME-01473

23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a Kd of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer.

For research use only. We do not sell to patients.

23ME-01473

23ME-01473 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

23ME-01473 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a Kd of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer[1].

Species Reactivity

Human
In Vitro

23ME-01473 (threefold serial dilutions; 37°C) binds to purified hULBP6, hULBP2 and hULBP5 proteins with high affinity, among which it shows the strongest affinity for hULBP6 (KD = 0.053 nmol/L), and does not bind to ULBP1, ULBP3 or ULBP4[1].
23ME-01473 (three-fold serial dilution; room temperature) potently blocks the binding of purified ULBP5 and ULBP6-02 to purified NKG2D, with a stronger inhibitory effect on ULBP6-02 (IC50 = 0.04 nmol/L) than on ULBP5 (IC50 = 0.31 nmol/L)[1].
23ME-01473 (threefold serial dilutions; 37°C) binds to purified activated hFcγ receptors with high affinity, particularly FcγRIIIa-V176 (KD = 6.74 nmol/L) and FcγRIIIa-F176 (KD = 25.50 nmol/L), while it shows low affinity for the inhibitory FcγRIIb[1].
23ME-01473 (0.05-200 nmol/L) significantly enhances IFNγ production by hPBMCs pre-stimulated with IL-2/IL-15 and co-cultured with COV644 cells and soluble ULBP6-02, and its activity is superior to that of the Fc-WT anti-ULBP6/ULBP2/ULBP5 variant[1].
23ME-01473 (100 nmol/L; 5 days) potently enhances the cytotoxicity of IL-2/IL-15-prestimulated hPBMC against COV644-GFP ovarian cancer cells in the presence of soluble ULBP6-02, and its activity is superior to that of effector function-impaired antibodies and isotype control antibodies[1].
23ME-01473 (0.0001-10 nmol/L; per assay protocol) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) against COV644 ovarian cancer cells via activating FcγRIIIa, and its activity is significantly higher than that of the Fc-WT anti-ULBP6/2/5 variant[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

23ME-01473 Related Antibodies
In Vivo

23ME-01473 (10 mg/kg, twice weekly for 6 weeks) induces tumor growth inhibition in NSCLC PDX models implanted with hNK cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: hIL-15 NOG mice (female, Taconic Inc.)[1]
Dosage: 10 mg/kg
Administration: twice weekly; 6 weeks
Result: Achieved 48% tumor growth inhibition compared with isotype control.
Showed slower tumor growth kinetics, particularly near the end of the dosing regimen, compared with control group.
Gene ID

154064  [NCBI]

Accession

Q5VY80
Target

ULBP-6/RAET1L
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

23ME-01473 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

23ME-01473Fc Receptor (FcR)C-type Lectin-like Receptors (CTLRs)Fc ReceptorNK cellsnon-small cell lung cancerovarian cancerT cellsULBP6ULBP2NKG2DFcγRIIIapatient-derived xenograft modelULBP5Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
23ME-01473
Cat. No.:
HY-P992163
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.